Abiopharma

🔍 KENNEY CHRISTOPHER JOHN (Executive)

Company: Xenon Pharmaceuticals Inc. (XENE)

Report Date: 2026-08-28

Detailed Transactions and Holdings:

• Sold 6,368 shares of Common Shares at $60.1673 per share (Direct)
  Date: 2026-08-28 | Code: S | equity_swap_involved: false | shares_owned_after: 702.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 700 shares of Common Shares at $60.9766 per share (Direct)
  Date: 2026-08-28 | Code: S | equity_swap_involved: false | shares_owned_after: 2.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.
• F2: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F3: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F4: The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4.